Skip to main content

Table 4 Pooled estimates of the Network meta-analysis for AE (lower triangle) and 3/4 AE (upper triangle)

From: Efficacy and safety of first-line CDK4/6 inhibitors plus AI therapy for patients with HR +/HER2- advanced breast cancer: a network meta-analysis

AI

65.56(25.61,167.82)

14.24(8.41,24.11)

10.89(4.81,24.67)

4.48 (2.44,8.20)

0.02 (0.00,0.46)

dalpi + Al

0.22 (0.07,0.64)

0.17 (0.05,0.58)

0.07 (0.02,0.21)

0.14 (0.04,0.45)

6.03(0.24,153.92)

palbo + Al

0.76 (0.29,2.02)

0.31 (0.14,0.70)

0.42 (0.08,2.26)

18.51(0.59,585.73)

3.07(0.39,24.20)

ribo + AI

0.41 (0.15,1.14)

0.12 (0.03,0.48)

5.46(0.20,149.35)

0.91 (0.17,4.89)

0.29 (0.03,2.59)

abema + AI

  1. dalpi, dalpiciclib, palbo palbociclib, abema abemaciclib, ribo ribociclib, AI aromatase inhibitor, AE Adverse event, 3/4 AE grade 3/4 of adverse event
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us